Cabozantinib (XL184) effective in Treating Castration-Resistant Prostate Cancer (CRPC) – Study
A new study carried out by researchers of the University of Michigan in Ann Arbor, has discovered that cabozantinib (XL184), the orally bioavaialable tyrosine kinase inhibitor has clinical activity in men with castration-resistant prostate cancer (CRPC).
The study’s findings have been published online in the “Journal of Clinical Oncology”. The November 19, 2012 publication revealed details on how the researchers came up with their conclusion.
A report published in Medical Xpress on December 3, 2012 provided at insights on how the research was carried out. Excerpts from the Medical Xpress post reveal: David C. Smith, M.D., of the University of Michigan in Ann Arbor, and colleagues conducted a phase II randomized discontinuation trial involving 171 men with CRPC to evaluate the activity of cabozantinib. Patients received 100 mg of cabozantinib each day, and those with stable disease at 12-weeks were randomized to receive cabozantinib or placebo. Based on the observed activity of cabozantinib, random assignment was stopped early. The researchers found that 72 percent of patients had regression in soft tissue lesions and 68 percent exhibited improvement on bone scan, including 12 percent with complete resolution.
At 12 weeks, the objective response rate was 5 percent, and 75 percent exhibited stable disease. The median progression-free survival was 23.9 and 5.9 weeks for cabozantinib- and placebo-treated patients, respectively (hazard ratio, 0.12).
In 57 percent of patients, there was a reduction of at least 50 percent in serum total alkaline phosphatase and plasma cross-linked C-terminal telopeptide of type I collagen. In a retrospective data review, bone pain was improved for 67 percent of patients, and narcotic use decreased by 56 percent. Fatigue, hypertension, and hand-foot syndrome were the most common grade 3 adverse events.
The study authors have expressed hope that Cabozantinib, which has substantial tumor suppressing property readily, helps in treating patients with advanced prostate cancer, more particular, that referred to as castration resistant prostate cancer (CRPC). The makers of Cabozantinib, Exelixis, support the clinical trials.
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:
(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)
- Cabozantinib Shows More Efficacy in Treating Metastatic Castration-Resistant Prostate Cancer (CRPC)
- Management of Castration-Resistant Prostate Cancer
- US Oncologists to Prescribe Enzalutamide for Metastatic Castration-resistant Prostate cancer (mCRPC)
- Enzalutamide Improves Survival for Castration- Resistant Prostate Cancer in Phase III Clinical Trial
- MicroRNA 125b, a Molecule and new Target for Castration Resistant Prostate Cancer Identified
- High-Dose Image-Guided IMRT for treating localized prostate cancer is Effective in a Medium Term Evaluation
- Researchers Discover New Functions of PARP-1 Inhibitor in Treating Advanced Prostate Cancer
- Promising Combination of Docetaxel and Novel Therapies Ongoing for prostate Cancer
- Treating Metastatic Prostate Cancer To The Bone
- Genetic Signatures Offer Clues about Prognosis in Castration-Resistance Prostate Cancer